Your Article Summary
See Latest ArticlesNew mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Leukemia and Lymphoma, 07/02/09
Mascarenhas CC et al. - D-HPLC is a practical and sensitive method for routine clinical monitoring for emergence of kinase domain mutations and may be useful for optimising therapy in CML. The screening of mutations in exon 6 is clinically relevant, once the presence of mutations confers a poor outcome. Early detection of emerging mutant clones may help in decision-making for alternative treatment.
Related Articles
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia
Blood, 11/13/09
Relevance Score: 87%
BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients
European Journal of Haematology, 11/04/09
Relevance Score: 87%
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Blood, 10/30/09
Relevance Score: 87%
Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation
Blood, 11/06/09
Relevance Score: 84%
Outcome of 125 children with CML who received transplants from unrelated donors: the Japan Marrow Donor Program (JMDP)
Biology of Blood and Marrow Transplantation, 10/07/09
Relevance Score: 84%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhibition of hepatoma 22 tumor by Liquiritigenin
Phytotherapy Research, 12/08/09
Carcinoid tumor of the kidney: An unusual renal tumor
Indian Journal of Urology, 12/08/09